vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Repay Holdings Corp (RPAY). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $78.6M, roughly 1.8× Repay Holdings Corp). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -178.3%, a 213.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 0.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $23.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -1.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Repay Holdings Corp is a leading payment technology provider delivering integrated end-to-end payment processing solutions for businesses across North America. Its offerings include credit/debit card processing, ACH transfer services, POS system integrations and digital payment tools, serving retail, healthcare, automotive and e-commerce segments to help clients streamline transaction workflows and boost operational efficiency.
ADMA vs RPAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $78.6M |
| Net Profit | $49.4M | $-140.1M |
| Gross Margin | 63.8% | 74.2% |
| Operating Margin | 45.1% | -182.2% |
| Net Margin | 35.5% | -178.3% |
| Revenue YoY | 18.4% | 0.4% |
| Net Profit YoY | -55.9% | -3304.1% |
| EPS (diluted) | $0.20 | $-1.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $78.6M | ||
| Q3 25 | $134.2M | $77.7M | ||
| Q2 25 | $122.0M | $75.6M | ||
| Q1 25 | $114.8M | $77.3M | ||
| Q4 24 | $117.5M | $78.3M | ||
| Q3 24 | $119.8M | $79.1M | ||
| Q2 24 | $107.2M | $74.9M | ||
| Q1 24 | $81.9M | $80.7M |
| Q4 25 | $49.4M | $-140.1M | ||
| Q3 25 | $36.4M | $-6.4M | ||
| Q2 25 | $34.2M | $-102.3M | ||
| Q1 25 | $26.9M | $-7.9M | ||
| Q4 24 | $111.9M | $-4.1M | ||
| Q3 24 | $35.9M | $3.2M | ||
| Q2 24 | $32.1M | $-4.1M | ||
| Q1 24 | $17.8M | $-5.2M |
| Q4 25 | 63.8% | 74.2% | ||
| Q3 25 | 56.3% | 74.4% | ||
| Q2 25 | 55.1% | 75.7% | ||
| Q1 25 | 53.2% | 75.9% | ||
| Q4 24 | 53.9% | 76.3% | ||
| Q3 24 | 49.8% | 77.8% | ||
| Q2 24 | 53.6% | 78.2% | ||
| Q1 24 | 47.8% | 76.2% |
| Q4 25 | 45.1% | -182.2% | ||
| Q3 25 | 38.0% | -3.9% | ||
| Q2 25 | 35.1% | -138.7% | ||
| Q1 25 | 30.4% | -4.7% | ||
| Q4 24 | 32.6% | -1.5% | ||
| Q3 24 | 33.1% | -0.9% | ||
| Q2 24 | 36.6% | -4.6% | ||
| Q1 24 | 26.7% | -3.1% |
| Q4 25 | 35.5% | -178.3% | ||
| Q3 25 | 27.1% | -8.3% | ||
| Q2 25 | 28.1% | -135.2% | ||
| Q1 25 | 23.4% | -10.3% | ||
| Q4 24 | 95.2% | -5.3% | ||
| Q3 24 | 30.0% | 4.1% | ||
| Q2 24 | 29.9% | -5.4% | ||
| Q1 24 | 21.7% | -6.5% |
| Q4 25 | $0.20 | $-1.68 | ||
| Q3 25 | $0.15 | $-0.08 | ||
| Q2 25 | $0.14 | $-1.15 | ||
| Q1 25 | $0.11 | $-0.09 | ||
| Q4 24 | $0.45 | $-0.04 | ||
| Q3 24 | $0.15 | $0.03 | ||
| Q2 24 | $0.13 | $-0.04 | ||
| Q1 24 | $0.08 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $115.7M |
| Total DebtLower is stronger | $72.1M | $280.1M |
| Stockholders' EquityBook value | $477.3M | $484.4M |
| Total Assets | $624.2M | $1.2B |
| Debt / EquityLower = less leverage | 0.15× | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $115.7M | ||
| Q3 25 | $61.4M | $95.7M | ||
| Q2 25 | $90.3M | $162.6M | ||
| Q1 25 | $71.6M | $165.5M | ||
| Q4 24 | $103.1M | $189.5M | ||
| Q3 24 | $86.7M | $168.7M | ||
| Q2 24 | $88.2M | $147.1M | ||
| Q1 24 | $45.3M | $128.3M |
| Q4 25 | $72.1M | $280.1M | ||
| Q3 25 | $72.4M | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | $72.3M | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $477.3M | $484.4M | ||
| Q3 25 | $431.2M | $616.9M | ||
| Q2 25 | $398.3M | $633.7M | ||
| Q1 25 | $373.4M | $755.7M | ||
| Q4 24 | $349.0M | $761.3M | ||
| Q3 24 | $231.9M | $754.7M | ||
| Q2 24 | $188.3M | $815.4M | ||
| Q1 24 | $153.7M | $813.8M |
| Q4 25 | $624.2M | $1.2B | ||
| Q3 25 | $568.7M | $1.3B | ||
| Q2 25 | $558.4M | $1.4B | ||
| Q1 25 | $510.6M | $1.5B | ||
| Q4 24 | $488.7M | $1.6B | ||
| Q3 24 | $390.6M | $1.6B | ||
| Q2 24 | $376.4M | $1.5B | ||
| Q1 24 | $350.9M | $1.5B |
| Q4 25 | 0.15× | 0.58× | ||
| Q3 25 | 0.17× | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | 0.21× | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $23.3M |
| Free Cash FlowOCF − Capex | $34.6M | $23.2M |
| FCF MarginFCF / Revenue | 24.8% | 29.6% |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $90.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $23.3M | ||
| Q3 25 | $13.3M | $32.2M | ||
| Q2 25 | $21.1M | $33.1M | ||
| Q1 25 | $-19.7M | $2.5M | ||
| Q4 24 | $50.2M | $34.3M | ||
| Q3 24 | $25.0M | $60.1M | ||
| Q2 24 | $45.6M | $31.0M | ||
| Q1 24 | $-2.2M | $24.8M |
| Q4 25 | $34.6M | $23.2M | ||
| Q3 25 | $-1.1M | $32.1M | ||
| Q2 25 | $18.7M | $33.0M | ||
| Q1 25 | $-24.4M | $2.4M | ||
| Q4 24 | $47.5M | $34.0M | ||
| Q3 24 | $24.0M | $59.8M | ||
| Q2 24 | $43.6M | $30.5M | ||
| Q1 24 | $-4.6M | $24.7M |
| Q4 25 | 24.8% | 29.6% | ||
| Q3 25 | -0.8% | 41.3% | ||
| Q2 25 | 15.3% | 43.6% | ||
| Q1 25 | -21.2% | 3.0% | ||
| Q4 24 | 40.4% | 43.5% | ||
| Q3 24 | 20.0% | 75.6% | ||
| Q2 24 | 40.7% | 40.7% | ||
| Q1 24 | -5.6% | 30.6% |
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.2% | ||
| Q2 25 | 2.0% | 0.1% | ||
| Q1 25 | 4.1% | 0.2% | ||
| Q4 24 | 2.3% | 0.3% | ||
| Q3 24 | 0.9% | 0.3% | ||
| Q2 24 | 1.9% | 0.6% | ||
| Q1 24 | 2.9% | 0.1% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 18.52× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
